CRP and hsCRP: The Inflammation Marker Your Standard Blood Panel Might Skip

What Is CRP — and Why Does It Matter?

Inflammation is central to many chronic diseases — heart disease, rheumatoid arthritis, type 2 diabetes. One of the most widely used markers to detect and monitor systemic inflammation is C-Reactive Protein, or CRP.

Most people have heard of cholesterol testing. Far fewer know about CRP — even though a landmark trial called JUPITER showed that a specialized form of this test (hs-CRP) could identify people at risk for heart attacks who would have been missed by cholesterol testing alone.

This article explains what CRP and hs-CRP measure, what your results mean, when doctors order it, and what it cannot tell you.

What CRP and hs-CRP Actually Measure

CRP is a pentameric protein produced by the liver in response to IL-6, TNF-alpha, and IL-1beta. Its role is to act as an opsonin — marking damaged cells and pathogens for immune destruction. In healthy people, CRP is below 1 mg/L; after an acute stimulus, it can exceed 100 mg/L within 24–48 hours. The IL-6/JAK/STAT3 pathway is the primary driver of CRP gene transcription.

Both tests measure the same protein. hs-CRP is a more precise ruler for the lower end of the scale — it was developed to accurately measure the 0.1–3 mg/L range that standard CRP assays cannot detect reliably.

Reference Ranges

Standard CRP ranges

hs-CRP cardiovascular risk categories (AHA/CDC)

Important: These categories are based on a single measurement. Guidelines recommend confirming an elevated result with repeat testing 2–4 weeks later before making clinical decisions, due to ~25–30% biological variability. Lp(a) and ApoB can complement hs-CRP for a comprehensive cardiovascular risk picture.

Factors that influence CRP: Age, sex, smoking, obesity, oral contraceptives, season, time of day, recent infection or vaccination.

When Doctors Order CRP — and Why

Acute care (standard CRP)

Differentiate bacterial from viral infections; monitor antibiotic response in pneumonia/sepsis; assess disease activity in RA/lupus/vasculitis/IBD; detect transplant rejection; gauge COVID-19 severity.

Primary care / preventive (hs-CRP)

Cardiovascular risk stratification; Reynolds Risk Score calculation; statin therapy decisions (JUPITER population); evaluation of unexplained fatigue with suspected chronic inflammation.

What guidelines say

2019 ACC/AHA: Class IIb — hs-CRP is reasonable in adults 40–75 being considered for primary prevention statin therapy when risk is uncertain. Not universal screening; a risk modifier.

2021 USPSTF: Insufficient evidence (I statement) for hs-CRP screening as standalone test in asymptomatic adults. Applies to screening, not clinical risk assessment.

CRP and Heart Disease — JUPITER and the Reynolds Risk Score

Inflammation and atherosclerosis

Atherosclerosis is now understood as an inflammatory disease. Cholesterol accumulation triggers immune infiltration; inflammatory cytokines destabilize plaques, making them prone to rupture and cause MI. CRP is a biomarker of this state.

The JUPITER Trial (2008)

• 17,802 men >50 / women >60 with LDL <130 mg/dL and hs-CRP ≥2.0 mg/L
• Randomized to rosuvastatin 20 mg/day vs. placebo
• Stopped early after median 1.9 years for overwhelming benefit

Key insight: Normal LDL + elevated hs-CRP = substantial statin benefit. The test identified a group cholesterol screening would miss. [Ridker PM, et al. NEJM. 2008;359(21):2195–2207]

Reynolds Risk Score

Incorporates age, BP, smoking, total cholesterol, HDL, hs-CRP (unique among risk calculators), and family history. Reclassified ~20–30% of intermediate-risk individuals. Free calculator at reynoldsriskscore.org. [Ridker PM, et al. Circulation. 2008;118(22):2243–2251]

Limitations

1. Lack of specificity: CRP rises in response to virtually any inflammatory stimulus. Elevated hs-CRP tells you inflammation is present, not where or why.

2. Biological variability: ~25–30% intra-individual variation. Repeat testing required to confirm elevation.

3. Short half-life (~19 hours): Reflects only a narrow time window; levels change rapidly.

4. Not all conditions raise CRP: In SLE, CRP can remain deceptively normal despite active disease (immune complex-mediated vs. IL-6-driven inflammation).

5. Not causally proven for CV disease: No RCT shows that lowering CRP directly reduces CV events independent of statins. JUPITER benefit may reflect statin anti-inflammatory effects.

The 2023 ACC Expert Consensus

Supports hs-CRP as risk modifier in intermediate-risk patients; recommends considering hs-CRP >2 mg/L as threshold for intensifying preventive therapy; notes emerging role of Lp(a) alongside hs-CRP as complementary markers. [Bhatt DL, et al. JACC. 2023;81(18):1848–1865]

The CANTOS Trial (2017)

Targeting IL-1beta with canakinumab reduced CV events in post-MI patients with elevated hs-CRP even when LDL was at target — first proof-of-concept that treating inflammation itself prevents CV events. [Ridker PM, et al. NEJM. 2017;377(12):1119–1131]

False positives

Acute infection, recent vaccination, chronic inflammatory disease, recent surgery/trauma, severe obesity, smoking, age >65.

False negatives

Chronic corticosteroid use, severe liver dysfunction, certain genetic polymorphisms.

CRP vs. ESR and IL-6

ESR reflects longer inflammatory windows; CRP is more responsive to acute changes. For CV risk, hs-CRP has largely supplanted ESR.

IL-6 vs. hs-CRP

IL-6 is the upstream driver of CRP production. Genetic studies (Mendelian randomization) suggest IL-6 may be causally related to CV disease while CRP may be a bystander. IL-6 receptor antagonists reduce CV events in RA patients. Routine clinical IL-6 measurement is not standard practice for CV risk assessment. [IL6R MR Consortium. Lancet. 2014;384(9941):343–345]

Frequently Asked Questions

What is a normal CRP level for a healthy person?
For standard CRP testing, values below 10 mg/L are within normal limits. For hs-CRP (cardiovascular testing), the goal is typically below 1.0 mg/L, with 1.0–3.0 mg/L representing average risk and above 3.0 mg/L representing elevated risk. CRP is not normally zero — even healthy individuals have detectable baseline levels, typically under 1 mg/L.

Is hs-CRP the same as regular CRP?
Both tests measure the same protein (C-Reactive Protein). Standard CRP accurately measures values above ~3–10 mg/L. hs-CRP was developed to accurately measure the much lower concentrations (0.1–3 mg/L) that predict cardiovascular risk. For heart disease risk assessment, ask for hs-CRP specifically.

Can a single CRP test diagnose heart disease?
No. CRP is a risk modifier, not a diagnostic test. An elevated hs-CRP indicates your body is in an inflammatory state — it does not diagnose heart disease or atherosclerosis. Your doctor will interpret an elevated CRP alongside cholesterol, blood pressure, family history, and other risk factors before making treatment recommendations.

Why do I need to repeat the CRP test?
CRP has significant biological variability — the same person can have meaningfully different results on different days depending on infections, stress, or other factors. Guidelines recommend confirming an elevated result with repeat testing 2–4 weeks later before making clinical decisions. A single elevated CRP is not sufficient to guide treatment.

Does CRP go up with a cold or flu?
Yes. Any acute infection — including common colds and influenza — can elevate CRP, sometimes substantially. Wait 2–4 weeks after full recovery before having hs-CRP measured for preventive cardiovascular purposes.

Can I lower my CRP without medication?
Yes. Multiple lifestyle interventions reduce CRP: smoking cessation, weight loss (adipose tissue produces IL-6), regular aerobic exercise, Mediterranean-style diet (olive oil, fish, vegetables, whole grains), alcohol moderation, and 7–9 hours of quality sleep.

Should I ask my doctor to order hs-CRP?
If you are middle-aged (40–75) and your cardiovascular risk is uncertain — borderline cholesterol or blood pressure, family history of early heart disease — it is reasonable to ask whether hs-CRP would add useful information. It is most informative for people at intermediate risk, where additional information can genuinely change treatment decisions.

What is the CANTOS trial and why does it matter?
The Canakinumab Anti-Inflammatory Thrombosis Outcomes Study (CANTOS) proved that targeting the IL-1beta pathway — upstream of CRP — could reduce cardiovascular events in post-MI patients with elevated hs-CRP even when LDL was at target. This was the first proof-of-concept that treating inflammation itself can prevent heart attacks. Low-dose colchicine (FDA-approved 2023) is now available for secondary prevention in patients with residual inflammatory risk.

Can CRP be too low?
There is no clinical condition associated with pathologically low CRP. Low CRP is simply "not elevated" — normal. Some people have a genetic makeup resulting in consistently lower CRP; this is not a health concern.